| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
DNA Topology Section, Laboratory of Molecular Pharmacology DTP, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255
Camptothecin (CPT) derivatives are a new family of anticancer agents which are selective inhibitors of DNA topoisomerase I (top1) and have entered clinical trials with promising results. The cellular determinants for CPT activity were studied in the seven cell lines of the National Cancer Institute anticancer screen. These cell lines exhibit natural differences in sensitivity to CPT and can be divided into three groups, according to their increasing resistance: colo205, SW620, HCT116<HT29, HCC2998<HCT15, and KM12. The differential sensitivity range was approximately 17-fold between KM12 and colo205 cells. CPT uptake varied only by less than a factor of three among the cell lines. Top1 mRNA, measured by Northern blotting analysis, and top1 protein levels, measured by Western blotting, varied by 2-fold or less among the cell lines and were correlated neither with the CPT cytotoxicity nor the levels of cleavable complexes measured by alkaline elution in the various cell lines. An overall log-linear correlation was observed between CPT-induced top1-cleavable complexes and growth inhibition, indicating the importance of cleavable complex formation rather than top1 levels for cell killing in this panel of cell lines. Also, some cell lines displayed marked growth inhibition differences with minimal differences in cleavable complexes and S-phase fraction, suggesting that parameters downstream from the cleavable complexes are also critical for CPT cytotoxicity.
1 Supported in part by a fellowship from the French Ligue Nationale contre le Cancer and from the National Cancer Institute/European Organisation for Research and Treatment of Cancer (to F. G.) and by a fellowship from Associazione Italiana per la Ricerca sul Cancro, Milano, Italy (to M. V.).
2 To whom requests for reprints should be addressed at, Laboratory of Molecular Pharmacology, National Cancer Institute, Bldg. 37, Room 5C25, NIH, Bethesda, MD 20892-4255.
Received 11/18/94. Accepted 3/16/95.
This article has been cited by other articles:
|
|
 |
|
  O. Sordet, A. Goldman, C. Redon, S. Solier, V. A. Rao, and Y. Pommier Topoisomerase I Requirement for Death Receptor-induced Apoptotic Nuclear Fission J. Biol. Chem., August 22, 2008; 283(34): 23200 - 23208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Desai, L. M. Wood, Y.-C. Tsai, T.-S. Hsieh, J. R. Marks, G. L. Scott, B. C. Giovanella, and L. F. Liu ISG15 as a novel tumor biomarker for drug sensitivity Mol. Cancer Ther., June 1, 2008; 7(6): 1430 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cummings, C. Hodgkinson, R. Odedra, P. Sini, S. P. Heaton, K. E. Mundt, T. H. Ward, R. W. Wilkinson, J. Growcott, A. Hughes, et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity Mol. Cancer Ther., March 1, 2008; 7(3): 455 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miknyoczki, H. Chang, J. Grobelny, S. Pritchard, C. Worrell, N. McGann, M. Ator, J. Husten, J. Deibold, R. Hudkins, et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity Mol. Cancer Ther., August 1, 2007; 6(8): 2290 - 2302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takemura, V. A. Rao, O. Sordet, T. Furuta, Z.-H. Miao, L. Meng, H. Zhang, and Y. Pommier Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks J. Biol. Chem., October 13, 2006; 281(41): 30814 - 30823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Luo, Q. He, X. He, Y. Hu, W. Lu, Y. Cheng, and B. Yang Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Mol. Cancer Ther., April 1, 2006; 5(4): 962 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Tomicic, M. Christmann, and B. Kaina Topotecan-Triggered Degradation of Topoisomerase I Is p53-Dependent and Impacts Cell Survival Cancer Res., October 1, 2005; 65(19): 8920 - 8926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Minderman, J. M. Conroy, K. L. O'Loughlin, D. McQuaid, P. Quinn, S. Li, L. Pendyala, N. J. Nowak, and M. R. Baer In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells Mol. Cancer Ther., June 1, 2005; 4(6): 885 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Shah, N. Kemeny, A. Hummer, M. Drobnjak, M. Motwani, C. Cordon-Cardo, M. Gonen, and G. K. Schwartz Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes Clin. Cancer Res., May 1, 2005; 11(9): 3296 - 3302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mross, H. Richly, N. Schleucher, S. Korfee, M. Tewes, M. E. Scheulen, S. Seeber, T. Beinert, M. Schweigert, U. Sauer, et al. A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors Ann. Onc., August 1, 2004; 15(8): 1284 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-F. Zhang, A. Tomida, R. Koshimizu, Y. Ogiso, S. Lei, and T. Tsuruo Cullin 3 Promotes Proteasomal Degradation of the Topoisomerase I-DNA Covalent Complex Cancer Res., February 1, 2004; 64(3): 1114 - 1121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Azrak, S. Cao, H. K. Slocum, K. Toth, F. A. Durrani, M.-b. Yin, L. Pendyala, W. Zhang, H. L. McLeod, and Y. M. Rustum Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts Clin. Cancer Res., February 1, 2004; 10(3): 1121 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Miknyoczki, S. Jones-Bolin, S. Pritchard, K. Hunter, H. Zhao, W. Wan, M. Ator, R. Bihovsky, R. Hudkins, S. Chatterjee, et al. Chemopotentiation of Temozolomide, Irinotecan, and Cisplatin Activity by CEP-6800, a Poly(ADP-Ribose) Polymerase Inhibitor Mol. Cancer Ther., April 1, 2003; 2(4): 371 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Motwani, F. M. Sirotnak, Y. She, T. Commes, and G. K. Schwartz Drg1, a Novel Target for Modulating Sensitivity to CPT-11 in Colon Cancer Cells Cancer Res., July 15, 2002; 62(14): 3950 - 3955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Chang, J.-F. Liu, S.-H. Juang, T.-W. Liu, and L.-T. Chen Novel Mutation of Topoisomerase I in Rendering Cells Resistant to Camptothecin Cancer Res., July 1, 2002; 62(13): 3716 - 3721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wu, M.-b. Yin, G. Hapke, K. Toth, and Y. M. Rustum Induction of Biphasic DNA Double Strand Breaks and Activation of Multiple Repair Protein Complexes by DNA Topoisomerase I Drug 7-Ethyl-10-hydroxy-camptothecin Mol. Pharmacol., April 1, 2002; 61(4): 742 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhou, F. G. Gwadry, W. C. Reinhold, L. D. Miller, L. H. Smith, U. Scherf, E. T. Liu, K. W. Kohn, Y. Pommier, and J. N. Weinstein Transcriptional Regulation of Mitotic Genes by Camptothecin-induced DNA Damage: Microarray Analysis of Dose- and Time-dependent Effects Cancer Res., March 1, 2002; 62(6): 1688 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pichierri, A. Franchitto, R. Piergentili, C. Colussi, and F. Palitti Hypersensitivity to camptothecin in MSH2 deficient cells is correlated with a role for MSH2 protein in recombinational repair Carcinogenesis, November 1, 2001; 22(11): 1781 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. De Cesare, G. Pratesi, P. Perego, N. Carenini, S. Tinelli, L. Merlini, S. Penco, C. Pisano, F. Bucci, L. Vesci, et al. Potent Antitumor Activity and Improved Pharmacological Profile of ST1481, a Novel 7-substituted Camptothecin Cancer Res., October 1, 2001; 61(19): 7189 - 7195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Guichard, A. Montazeri, E. Chatelut, I. Hennebelle, R. Bugat, and P. Canal Schedule-dependent Activity of Topotecan in OVCAR-3 Ovarian Carcinoma Xenograft: Pharmacokinetic and Pharmacodynamic Evaluation Clin. Cancer Res., October 1, 2001; 7(10): 3222 - 3228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jacob, M. Aguado, D. Fallik, and F. Praz The Role of the DNA Mismatch Repair System in the Cytotoxicity of the Topoisomerase Inhibitors Camptothecin and Etoposide to Human Colorectal Cancer Cells Cancer Res., September 1, 2001; 61(17): 6555 - 6562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Desai, T.-K. Li, A. Rodriguez-Bauman, E. H. Rubin, and L. F. Liu Ubiquitin/26S Proteasome-mediated Degradation of Topoisomerase I As a Resistance Mechanism to Camptothecin in Tumor Cells Cancer Res., August 1, 2001; 61(15): 5926 - 5932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview J. Clin. Oncol., March 1, 2001; 19(5): 1501 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Rothenberg Irinotecan (CPT-11): Recent Developments and Future Directions-Colorectal Cancer and Beyond Oncologist, February 1, 2001; 6(1): 66 - 80. [Abstract] [Full Text]
|
|
|
|
|
|
M.-L. Li, L. Horn, P. S. Firby, and M. J. Moore Pharmacological Determinants of 9-Aminocamptothecin Cytotoxicity Clin. Cancer Res., January 1, 2001; 7(1): 168 - 174. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Huang, C. M. Horvath, and S. Waxman Regrowth of 5-Fluorouracil-treated Human Colon Cancer Cells Is Prevented by the Combination of Interferon {{gamma}}, Indomethacin, and Phenylbutyrate Cancer Res., June 1, 2000; 60(12): 3200 - 3206. [Abstract] [Full Text]
|
|
|
|
|
|
J. C. Cusack Jr., R. Liu, and A. S. Baldwin Jr. Inducible Chemoresistance to 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) in Colorectal Cancer Cells and a Xenograft Model Is Overcome by Inhibition of Nuclear Factor-{{kappa}}B Activation Cancer Res., May 1, 2000; 60(9): 2323 - 2330. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. H. Kaufmann, P. A. Svingen, S. D. Gore, D. K. Armstrong, Y.-C. Cheng, and E. K. Rowinsky Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells Blood, March 15, 1997; 89(6): 2098 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Edwards, A. Saleem, J. A. Shaman, T. Dennis, C. Gerigk, E. Oliveros, M. R. Gartenberg, and E. H. Rubin Role for Nucleolin/Nsr1 in the Cellular Localization of Topoisomerase I J. Biol. Chem., November 10, 2000; 275(46): 36181 - 36188. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
